Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The long-term replacement therapy with the dopamine (DA) precursor 3,4-dihydroxy-l-phenylalanine (L-DOPA) is a milestone in the treatment of Parkinson's disease (PD). Although this drug precursor can be metabolized into the active neurotransmitter DA throughout the brain, its therapeutic benefit is due to restoring extracellular DA levels within the dorsal striatum, which lacks endogenous DA as a consequence of the neurodegenerative process induced by the disease. In the early phases of PD, L-DOPA treatment is able to restore both long-term depression (LTD) and long-term potentiation (LTP), two major forms of corticostriatal synaptic plasticity that are altered by dopaminergic denervation. However, unlike physiological DA transmission, this therapeutic approach in the advanced phase of the disease leads to abnormal peaks of DA, non-synaptically released, which are supposed to trigger behavioural sensitization, namely L-DOPA-induced dyskinesia. This condition is characterized by a loss of synaptic depotentiation, an inability to reverse previously induced LTP. In the advanced stages of PD, L-DOPA can also induce non-motor fluctuations with cognitive dysfunction and neuropsychiatric symptoms such as compulsive behaviours and impulse control disorders. Although the mechanisms underlying the role of L-DOPA in both motor and behavioural symptoms are still incompletely understood, recent data from electrophysiological and imaging studies have increased our understanding of the function of the brain areas involved and of the mechanisms implicated in both therapeutic and adverse actions of L-DOPA in PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Synaptic tagging and long-term potentiation
Frey, U., & Morris, R. G. M. (1997) · Nature · doi:10.1038/385533a0 · Cited by 1,736
Surmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203
Dichotomous dopaminergic control of striatal synaptic plasticity
Shen, W., Flajolet, M., Greengard, P., & Surmeier, D. J. (2008) · Science · doi:10.1126/science.1160575 · Cited by 1,190
Strafella, A. P., Paus, T., Barrett, J., & Dagher, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-j0003.2001 · Cited by 1,058
Cools, R. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.12.1136 · Cited by 906 · cited 2×
“In particular, it has been postulated that the beneficial effect of L-DOPA on task-switching reflects a compensation of DA levels in depleted dorsal frontostriatal circuitry, whereas the impairing effect of L-DOPA on reversal learning reflects a detrimental ‘over-dosing’ of intact ventral frontostriatal circuitry [87,…”
BackgroundA cellular mechanism of reward-related learning
Reynolds, J. N. J., Hyland, B. I., & Wickens, J. R. (2001) · Nature · doi:10.1038/35092560 · Cited by 879 · cited 1×
“The requirement of a rise in intracellular calcium [69] and the concomitant activation of both glutamate and dopaminergic inputs [70] for the induction of striatal LTP was further supported by in vivo electrophysiological studies.”
ResultDopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Self-citationLoss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821 · cited 6×
“These findings show that the development of LIDs is associated with abnormal information storage in corticostriatal synapses [16].”
BackgroundInfluentialSelf-citationDay, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., Wokosin, D., Ilijic, E., Sun, Z., Sampson, A. R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1632 · Cited by 745
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens
Russo, S. J., Dietz, D. M., Dumitriu, D., Morrison, J. H., Malenka, R. C., & Nestler, E. J. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.02.002 · Cited by 654
A critical time window for dopamine actions on the structural plasticity of dendritic spines
Yagishita, S., Hayashi-Takagi, A., Ellis-Davies, G. C. R., Urakubo, H., Ishii, S., & Kasai, H. (2014) · Science · doi:10.1126/science.1255514 · Cited by 614
Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior
Goto, Y., & Grace, A. A. (2005) · Nature Neuroscience · doi:10.1038/nn1471 · Cited by 576 · cited 1×
“These synaptic and electrophysiological effects can, in turn, control goal-directed behaviour [93].”
BackgroundNeurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum
Lovinger, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.008 · Cited by 488 · cited 1×
“DA also regulates the plasticity of striatal neurons by modulating glutamatemediated LTD, LTP and synaptic depotentiation [54,55].”
BackgroundCompulsive drug use linked to sensitized ventral striatal dopamine transmission.
Evans, A. H., Pavese, N., Lawrence, A. D., Tai, Y. F., Appel, S., Doder, M., Brooks, D. J., Lees, A. J., & Piccini, P. (2006) · Annals of Neurology · doi:10.1002/ana.20822 · Cited by 473 · cited 1×
“In a study that analysed D2-like DA receptor binding through the use of positron emission tomography, it has been observed that PD patients with a DA dysregulation syndrome exhibit enhanced L-DOPA-induced ventral striatal DA release compared with L-DOPA-treated patients not compulsively taking dopaminergic drugs [89].”
BackgroundNeurobiological Mechanisms of Placebo Responses
Zubieta, J., & Stohler, C. S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04424.x · Cited by 277
Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective
Robbins, T. W., & Cools, R. (2014) · Movement Disorders · doi:10.1002/mds.25853 · Cited by 235
Synaptic plasticity in the mesolimbic dopamine system
Thomas, M. J., & Malenka, R. C. (2003) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2002.1236 · Cited by 137 · cited 1×
“In fact, medium spiny neurons of the ventral striatum express both LTD and LTP with some similarities with the features of these forms of synaptic plasticity in the dorsal striatum [90].”
BackgroundSerotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131 · cited 1×
“An increasing number of findings support the view that, in the advanced phase of PD and in the presence of a massive degeneration of nigrostriatal terminals, DA is released as a false neurotransmitter from the striatal serotonin terminals and this might act as a critical presynaptic factor underlying LIDs [13].”
BackgroundBagetta, V., Sgobio, C., Pendolino, V., Del Papa, G., Tozzi, A., Ghiglieri, V., Giampà, C., Zianni, E., Gardoni, F., Calabresi, P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2664-12.2012 · Cited by 74 · cited 2×
“Electrophysiological experiments and behavioural analysis have compared the effects of L-DOPA to those of pramipexole, a D2 receptor agonist widely used in PD therapy [76].”
BackgroundSelf-citation
Cited by
Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control
Speranza, L., di Porzio, U., Viggiano, D., de Donato, A., & Volpicelli, F. (2021) · Cells · doi:10.3390/cells10040735 · Cited by 415
Wang, Y., Tong, Q., Ma, S.-R., Zhao, Z.-X., Pan, L.-B., Cong, L., Han, P., Peng, R., Yu, H., Lin, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00456-5 · Cited by 319
Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
“These data suggest that L-dopa may produce a long-lasting beneficial effect on symptom progression, which is likely mediated by the plasticity of corticostriatal and nigrostriatal signaling in the striatum (Surmeier et al., 2007; Calabresi et al., 2015; Albin and Leventhal, 2017; Zhai et al., 2019).”
BackgroundVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
“For instance, long-term Levodopa use appears to affect synaptic plasticity and may increase synaptic density through levodopa-induced dyskinesia (Calabresi et al., 2015; Hurley et al., 2005; Martin et al., 2023).”
BackgroundPromising therapeutic agents for the treatment of Parkinson’s disease
Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1164687 · Cited by 7
Metadata
- Authors
- Calabresi, P., Ghiglieri, V., Mazzocchetti, P., Corbelli, I., & Picconi, B.
- Venue
- Philosophical Transactions of the Royal Society B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 2015-07-05
- Volume
- 370
- Issue
- 1672
- Pages
- 20140184
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2177709963
- Cited by
- 112
- References
- 21
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.